DTIL / Precision BioSciences (DTIL) Reports Q2 Loss, Misses Revenue Estimates

The heavy selling pressure might have exhausted for Precision BioSciences (DTIL) as it is technically in oversold territory now. In addition to this t more_horizontal

Precision BioSciences (DTIL) came out with a quarterly loss of $0.10 per share versus the Zacks Consensus Estimate of a loss of $0.23. This compares t more_horizontal

Precision Biosciences has been on a roll with positive updates in both their CAR T-Cell and gene editing pipelines. Unfortunately, the market has yet more_horizontal

Precision BioSciences (DTIL) came out with a quarterly loss of $0.23 per share versus the Zacks Consensus Estimate of a loss of $0.22. This compares t more_horizontal

Precision BioSciences (DTIL) delivered earnings and revenue surprises of -8.33% and 78%, respectively, for the quarter ended December 2022. Do the num more_horizontal

DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL) a clinical stage gene editing company developing ARCUS®-based ex vivo allog more_horizontal

Precision BioSciences has been on the candidate list for my Compounding Healthcare “Bio Boom” Portfolio. I am looking to find a spot for DTIL ahea more_horizontal

Precision BioSciences (DTIL) delivered earnings and revenue surprises of -2.33% and 23.80%, respectively, for the quarter ended June 2022. Do the numb more_horizontal